4.80 (-%)
As of Nov 21, 2024
Source:
Genenta Science S.p.a is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment ofsolid tumors. We have developed a novel biologic platform that involves the ex-vivo gene transfer of a therapeutic candidate intoautologous hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly to the tumor by infiltratingmonocytes/macrophages.
Country | Italy |
Headquarters | milan |
Phone Number | 39-02-2643-6639 |
Industry | |
CEO | Pierluigi Paracchi |
Website | genenta.com |